2Tamura K,Okamoto I,Kashii T,et al.Multicentre prospective phase Ⅱ trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations:results of the West Japan Thoracic Ontology Group trial (WJTOG0403)[J].Br J Cancer,2008,98(5):907-914. 被引量：1
3Parra HS,Cavina R,Latteri F,et al.Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (Iressa',ZD1839) in non-small cell lung cancer[J].Br J Cancer,2004,91(2):208-212. 被引量：1
4Tsao MS,Sakurada A,Cutz JC,et al.Edotinib in lung cancer:molecular and clinical predictors of outcome[J].N Engl J Med,2005,353(2):133-144. 被引量：1
5Pinter F,Papay J,Almasi A,et al.Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenoearcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry[J].J Mol Diagan,2008,10(2):160-168. 被引量：1
6Kim KS,Jeong JY,Kim YC,et al.Predictors of the response to gefitinib in refractory non-small cell lung cancer[J].Clin Cancer Res,2005,11(6):2244-2251. 被引量：1
7Kang SM,Kang HJ,Shin JH,et al.Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung[J].Cancer,2007,109(3):581-587. 被引量：1
8Dacic S,Flanagan M,Cieply K,et al.Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma[J].Am J Clin Pathol,2006,125(6):860-865. 被引量：1
10Li AR,Chitale D,Riely GJ,et al.EGFR mutations in lung adenocarcinomas:clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression[J].J Mol Diagn,2008,10(3):242-248. 被引量：1
